Research Topics
| G J NoelSummaryAffiliation: Johnson and Johnson Pharmaceutical Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infectionsGary J Noel
Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, USA
Clin Infect Dis 46:647-55. 2008....- Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disordersGary J Noel
Johnson and Johnson Pharmaceutical Research and Development LLC, Raritan, NJ 08869, USA
Pediatr Infect Dis J 26:879-91. 2007..A large prospective trial is needed to assess the risks associated with using levofloxacin in children... - Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteriaGary J Noel
Johnson and Johnson Pharmaceutical Research and Development, LLC, 900 Route 202, Raritan, NJ 08869, USA
Antimicrob Agents Chemother 52:37-44. 2008..The results of this trial support the use of ceftobiprole as an effective and well-tolerated treatment option for patients with cSSSIs caused by a spectrum of gram-positive bacteria... - Clinical profile of ceftobiprole, a novel beta-lactam antibioticG J Noel
Johnson and Johnson Pharmaceutical Research and Development, L L C, 900 Route 202, Raritan, NJ 08869, USA
Clin Microbiol Infect 13:25-9. 2007.... - A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis mediaGary J Noel
Johnson and Johnson Pharmaceutical Research and Development, L L C, Raritan, NJ 08869, USA
Pediatr Infect Dis J 27:483-9. 2008..The need for alternative antimicrobial therapy for recurrent and persistent acute otitis media (AOM) in children has raised interest in assessing the efficacy and safety of fluoroquinolones for treatment of these infections... - Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infectionsHolly Kimko
Johnson and Johnson Pharmaceutical Research and Development, LLC, South Raritan, NJ 08869, USA
Antimicrob Agents Chemother 53:1228-30. 2009..Dosing adjustments based on CL(CR) for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function... - Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacyKaren Bush
Johnson and Johnson Pharmaceutical Research and Development L L C, Raritan, NJ, USA
Expert Opin Investig Drugs 16:419-29. 2007..The future of all of these agents will depend on their clinical efficacy, safety and their ability to be accepted as beta-lactams for the reliable treatment of a broad spectrum of infections, including those caused by MRSA... - Characterization and dynamics of middle ear fluid and nasopharyngeal isolates of Streptococcus pneumoniae from 12 children treated with levofloxacinTodd A Davies
Johnson and Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869, USA
Antimicrob Agents Chemother 52:378-81. 2008..All nasopharynx isolates (n = 59) from 12 children were levofloxacin susceptible without parC/E or gyrA/B mutations. Pneumococcal nasopharynx persistence was not associated with levofloxacin resistance... - Effects of three fluoroquinolones on QT interval in healthy adults after single dosesGary J Noel
Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08869, USA
Clin Pharmacol Ther 73:292-303. 2003..A clinical trial was conducted in healthy adult volunteers to assess the effect of levofloxacin, moxifloxacin, and ciprofloxacin on the QT and QTc interval... - Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infectionsHolly Kimko
Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869, USA
Antimicrob Agents Chemother 53:3371-4. 2009..A ceftobiprole regimen of 500 mg every 8 h as a 2-h infusion has a high probability of achieving a target of >or=30 or >or=50% T>MIC for patients with cSSSI due to gram-positive and gram-negative pathogens... - Levofloxacin pharmacokinetics in childrenShuchean Chien
Johnson and Johnson Pharmaceutical Research and Development, LLC, 920 Route 202 South, PO Box 300, Raritan, NJ 08869-0602, USA
J Clin Pharmacol 45:153-60. 2005.... - Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordingsGary J Noel
UMDNJ-Newark, Johnson and Johnson Pharmaceutical Research and Development, L.L.C, 920 Route 202, Box 300, Raritan, NJ 08869, USA
J Clin Pharmacol 44:464-73. 2004..This work suggests that using continuous ECG recordings in assessing QT/QTc effects of drugs may be of value, particularly with drugs that might influence HR... - Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycinChuen L Yee
Johnson and Johnson Pharmaceutical Research and Development, L.L.C, Raritan, NJ 08869, USA
Pediatr Infect Dis J 21:525-9. 2002.... - Comparative study of levofloxacin in the treatment of children with community-acquired pneumoniaJohn S Bradley
Children s Hospital and Health Center, San Diego, CA, USA
Pediatr Infect Dis J 26:868-78. 2007..Levofloxacin has established efficacy and safety in the treatment of community-acquired pneumonia (CAP) in adults, and its use as an alternative therapy for children with CAP has been proposed... - Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjectsThomas P Lodise
Ordway Research Institute, Albany, NY 12208, USA
Antimicrob Agents Chemother 51:2378-87. 2007..v. q12h, for patients who had a creatinine clearance rate of < or =50 ml/min, was identified as the most appropriate treatment regimen for patients who require renal dose adjustment for mild to moderate renal impairment... - An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis mediaAdriano Arguedas
Instituto de Atención Pediátrica, Neeman ICIC, Universidad de Ciencias Medicas, San Jose, Costa Rica
Pediatr Infect Dis J 25:1102-9. 2006..Levofloxacin has excellent activity against common respiratory pathogens and therefore is likely to be effective in treating children with persistent or recurrent otitis media... - Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United StatesJames A Karlowsky
Focus Technologies, Herndon, Virginia 20171, USA
Antimicrob Agents Chemother 47:1790-7. 2003..pneumoniae were susceptible to levofloxacin. If fluoroquinolones become a treatment option for pediatric patients, careful monitoring of fluoroquinolone susceptibilities will be increasingly important in future surveillance studies... - Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care populationJohn D Seeger
i3 Drug Safety, Auburndale, MA, USA
Pharmacoepidemiol Drug Saf 15:784-92. 2006..We sought to quantify the strength of association between exposure to fluoroquinolone antibiotics and the occurrence of ATR, accounting for other risk factors... - Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo modelMurli U Purswani
Division of Pediatric Infectious Diseases and Immunology, Weill Medical College of Cornell University, NY, USA
J Antimicrob Chemother 50:51-8. 2002..This effect may influence the course of infection in a manner that is independent of the drug's antimicrobial activity...